Evercore ISI Cuts Becton, Dickinson and Company (NYSE:BDX) Price Target to $285.00

Becton, Dickinson and Company (NYSE:BDX) had its price objective lowered by Evercore ISI from $290.00 to $285.00 in a research note issued to investors on Tuesday morning, Benzinga reports. The brokerage currently has an outperform rating on the medical instruments supplier’s stock.

BDX has been the topic of a number of other research reports. Barclays boosted their price target on shares of Becton, Dickinson and Company from $305.00 to $312.00 and gave the company an overweight rating in a report on Monday, May 6th. StockNews.com lowered shares of Becton, Dickinson and Company from a buy rating to a hold rating in a report on Thursday, June 27th. Finally, The Goldman Sachs Group began coverage on shares of Becton, Dickinson and Company in a report on Thursday, May 30th. They set a buy rating and a $274.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of Moderate Buy and an average target price of $280.86.

Becton, Dickinson and Company Stock Down 0.0 %

BDX stock opened at $229.20 on Tuesday. Becton, Dickinson and Company has a 12 month low of $224.00 and a 12 month high of $287.32. The firm has a market cap of $66.24 billion, a PE ratio of 50.48, a P/E/G ratio of 2.05 and a beta of 0.42. The firm has a 50 day simple moving average of $234.27 and a 200 day simple moving average of $237.76. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.41 and a quick ratio of 0.97.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 EPS for the quarter, beating the consensus estimate of $2.97 by $0.20. Becton, Dickinson and Company had a net margin of 6.76% and a return on equity of 13.90%. The business had revenue of $5.05 billion during the quarter, compared to analyst estimates of $5.04 billion. During the same period in the prior year, the business earned $2.86 earnings per share. The business’s quarterly revenue was up 4.6% on a year-over-year basis. Equities research analysts forecast that Becton, Dickinson and Company will post 13.04 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 28th. Shareholders of record on Monday, June 10th were paid a $0.95 dividend. The ex-dividend date of this dividend was Monday, June 10th. This represents a $3.80 annualized dividend and a yield of 1.66%. Becton, Dickinson and Company’s dividend payout ratio is presently 83.70%.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 300 shares of the company’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $239.31, for a total value of $71,793.00. Following the transaction, the senior vice president now owns 1,976 shares in the company, valued at approximately $472,876.56. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 300 shares of the company’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $239.31, for a total value of $71,793.00. Following the transaction, the senior vice president now owns 1,976 shares in the company, valued at approximately $472,876.56. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Roland Goette sold 3,300 shares of the stock in a transaction on Monday, May 13th. The stock was sold at an average price of $236.70, for a total transaction of $781,110.00. Following the transaction, the executive vice president now owns 14,608 shares in the company, valued at approximately $3,457,713.60. The disclosure for this sale can be found here. In the last quarter, insiders have sold 8,615 shares of company stock worth $2,033,381. 0.31% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Livelsberger Financial Advisory bought a new stake in shares of Becton, Dickinson and Company during the 4th quarter worth $27,000. OLD Point Trust & Financial Services N A bought a new stake in shares of Becton, Dickinson and Company during the 4th quarter worth $29,000. DiNuzzo Private Wealth Inc. bought a new stake in shares of Becton, Dickinson and Company during the 4th quarter worth $30,000. Scarborough Advisors LLC bought a new stake in shares of Becton, Dickinson and Company during the 4th quarter worth $32,000. Finally, Fortitude Family Office LLC bought a new stake in shares of Becton, Dickinson and Company during the 4th quarter worth $35,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.